India to France: Verapamil Export Trade Route

The India to France Verapamil corridor is one of India's established pharmaceutical export routes, with 49 shipments documented worth a combined $15.4M USD. The route is dominated by MYLAN LABORATORIES LIMITED, which alone accounts for roughly 94% of all export value, reflecting the consolidated nature of India's verapamil manufacturing sector.

Across 2 active suppliers, the average shipment value stands at $315.1K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 75% of all shipments, consistent with verapamil's non-urgent bulk-order profile.

Shipment activity peaks during January–March, with an average transit time of 31 days port-to-port. The route has recorded an annual growth rate of 10.4%, placing it at rank #7 among India's top verapamil export destinations globally.

On the import side, key buyers of Indian verapamil in France include CSP VIATRIS SANTE AT CSP-LAB, CSP VIATRIS SANTE AT CSP- LAB,, CSP VIATRIS SANTE AT CSP- LABO, and 8 others. CSP VIATRIS SANTE AT CSP-LAB is the single largest importer with 4 shipments valued at $7.2M USD.

India's verapamil exports to France are driven primarily by a handful of large-scale manufacturers. MYLAN LABORATORIES LIMITED with 38 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 2 active exporters signals a competitive but concentrated market — buyers in France benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — MYLAN LABORATORIES LIMITED, MYLAN LABORATORIES LIMITED — together account for 100% of total trade value on this route. The average shipment value of $315.1K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as harmless medicines, verapamil mylan pharma l.p. 240 mg 30bl (40840 packs) and harmless medicines, verapamil mylan pharma l.p. 240 mg 30bl (40166 packs), suggesting that buyers in France tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, CSP VIATRIS SANTE AT CSP-LAB is the largest importer with 4 shipments worth $7.2M USD — representing 46% of all verapamil imports from India on this route. A total of 11 buyers are active on this corridor.